山楂叶总黄酮对非酒精性脂肪性肝病细胞病理及血脂影响的实验研究

Experimental study on the effects of Hawthorn Leaves Flavonoids on the pathology and blood lipid of NAFLD cells

目的:探讨山楂叶总黄酮(HLF)对非酒精性脂肪性肝病(NAFLD)细胞病理及血脂影响的干预机制。方法:采用肝L-02细胞诱导建立NAFLD模型,分为正常组、模型组、水飞蓟素组和山楂叶总黄酮(HLF)组共4组,运用HLF进行干预,检测肝细胞的抑制率、甘油三酯(TG)及超微量Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶的活性,并观察肝细胞超微病理改变。结果:模型组细胞生长明显受抑制,HLF药物组细胞生长的抑制率显著低于模型组,组间比较有极显著差异(P<0.01或P<0.05)。HLF药物组降低TG,提高超微量Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶的活力与模型组相比较有极显著差异(P<0.01)。模型组肝细胞线粒体水肿,外膜破裂,细胞核形状改变,呈凋亡特征性改变;HLF药物组肝细胞病理损伤较模型组明显改善。结论:HLF能显著降低NAFLD肝细胞的生长抑制率,减轻NAFLD对肝细胞的病理损伤,能降低TG并提高超微量Na+-K+-ATP酶、Ca2+-Mg2+-ATP酶的活力,干预脂肪性肝病的进展。

Objective： To explore the intervention mechanism of HLF on the effect of NAFLD cells pathological changes and blood lipid.Methods： Adopt NAFLD model induced by hepatic L-02 cells,The Experiment were divided into 4 groups： the normal group,the model group,the silymarin group and the HLF group. Using HLF to intervene NAFLD cells,to detect the inhibition rate of liver cells,triglyceride,u Na^＋-K^＋-ATPase and u Ca^2＋-Mg^2＋-ATPase,and observe the ultrastructural changes of liver cells. Results： The growth of the model group cell was obviously inhibited,the inhibitory rate of cell growth in the HLF drug group was significantly lower than that in the model group,and there was a significant difference between the groups（ P〈0. 01 or P〈0. 05）. In the HLF drug group,triglycer-ide decreased and the activity of u Na^＋-K^＋-ATPase and u Ca^2＋-Mg^2＋-ATPase was significantly different from that of the model group（ P〈0. 01）. In the model group,the hepatocyte mitochondria were edema,the outer membrane ruptured,and the nucleus shape changed,and the apoptosis was changed. The pathological damage of hepatocytes in the HLF group was significantly better than that in the model group. Conclusion： HLF can significantly reduce the growth inhibition rate of NAFLD hepatocytes,reduce the pathological damage of NAFLD to hepatocytes,reduce TG and increase the activity of u Na^＋-K^＋-ATPase and u Ca^2＋-Mg^2＋-ATPase,and intervene the progression of fatty liver disease.